$CTSO
Cytosorbents Corp Stock $ctso

$ctso Overview Financials Valuation SEC Filings Company Website

2015 Q1 Form 10-Q Financial Statement

#000114420415028999 Filed on May 11, 2015

Income Statement

Concept	2015 Q1	2014 Q1
Revenue	$723.1K	$1.062M
YoY Change	-31.92%	186.05%
Cost Of Revenue	$304.5K	$662.5K
YoY Change	-54.04%	161.34%
Gross Profit	$418.6K	$399.6K
YoY Change	4.74%	239.19%
Gross Profit Margin	57.89%	37.62%
Selling, General & Admin	$1.515M	$1.081M
YoY Change	40.23%	76.22%
% of Gross Profit	361.97%	270.38%
Research & Development	$951.0K	$236.8K
YoY Change	301.66%	-66.37%
% of Gross Profit	227.2%	59.25%
Depreciation & Amortization	$20.00K	$20.00K
YoY Change	0.0%	100.0%
% of Gross Profit	4.78%	5.0%
Operating Expenses	$2.682M	$1.554M
YoY Change	72.59%	0.89%
Operating Profit	-$2.712M	-$1.154M
YoY Change	134.94%	-18.85%
Interest Expense	$2.613K	-$137.1K
YoY Change	-101.91%	-33.68%
% of Operating Profit
Other Income/Expense, Net	-$2.454M	$179.1K
YoY Change	-1470.0%	-186.65%
Pretax Income	-$4.717M	-$975.1K
YoY Change	383.75%	-40.14%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$4.717M	-$975.1K
YoY Change	383.75%	-40.14%
Net Earnings / Revenue	-652.35%	-91.8%
Basic Earnings Per Share	-$0.19
Diluted Earnings Per Share	-$0.19	-$83.83K
COMMON SHARES
Basic Shares Outstanding	24.64M shares	298.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q1	2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.40M	$11.20M
YoY Change	19.64%	700.0%
Cash & Equivalents	$10.42M	$6.416M
Short-Term Investments	$2.900M	$4.700M
Other Short-Term Assets	$100.0K	$200.0K
YoY Change	-50.0%	100.0%
Inventory	$702.9K	$146.5K
Prepaid Expenses
Receivables	$700.0K	$300.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$14.88M	$11.83M
YoY Change	25.82%	455.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$330.3K	$155.4K
YoY Change	112.55%	11.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$652.2K	$409.7K
YoY Change	59.2%	59.07%
Total Long-Term Assets	$982.5K	$565.1K
YoY Change	73.87%	42.23%
TOTAL ASSETS
Total Short-Term Assets	$14.88M	$11.83M
Total Long-Term Assets	$982.5K	$565.1K
Total Assets	$15.86M	$12.39M
YoY Change	28.01%	390.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$475.2K	$527.6K
YoY Change	-9.94%	-25.13%
Accrued Expenses	$700.0K	$400.0K
YoY Change	75.0%	33.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$1.700M
YoY Change
Total Short-Term Liabilities	$6.198M	$3.299M
YoY Change	87.91%	232.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.198M	$3.299M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$6.200M	$3.300M
YoY Change	87.88%	232.18%
SHAREHOLDERS EQUITY
Retained Earnings	-$129.1M
YoY Change
Common Stock	$24.68K	$299.0K
YoY Change	-91.75%	30.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.666M	-$7.259M
YoY Change
Total Liabilities & Shareholders Equity	$15.86M	$12.39M
YoY Change	28.01%	390.48%

Cashflow Statement

Concept	2015 Q1	2014 Q1
OPERATING ACTIVITIES
Net Income	-$4.717M	-$975.1K
YoY Change	383.75%	-40.14%
Depreciation, Depletion And Amortization	$20.00K	$20.00K
YoY Change	0.0%	100.0%
Cash From Operating Activities	-$2.409M	-$800.1K
YoY Change	201.08%	-1.16%
INVESTING ACTIVITIES
Capital Expenditures	$104.0K	$21.37K
YoY Change	386.69%	877.58%
Acquisitions
YoY Change
Other Investing Activities	-$990.0K	-$4.750M
YoY Change	-79.16%
Cash From Investing Activities	-$1.135M	-$4.771M
YoY Change	-76.22%	218148.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$9.409M	$9.451M
YoY Change	-0.44%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$10.01M	$9.803M
YoY Change	2.13%	2078.49%
NET CHANGE
Cash From Operating Activities	-$2.409M	-$800.1K
Cash From Investing Activities	-$1.135M	-$4.771M
Cash From Financing Activities	$10.01M	$9.803M
Net Change In Cash	$6.468M	$4.232M
YoY Change	52.83%	-1270.26%
FREE CASH FLOW
Cash From Operating Activities	-$2.409M	-$800.1K
Capital Expenditures	$104.0K	$21.37K
Free Cash Flow	-$2.513M	-$821.5K
YoY Change	205.91%	1.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10418627	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3605280	USD
CY2015Q1	us-gaap	Short Term Investments ShortTermInvestments	2939000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	1944547	USD
CY2015Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	672676	USD
CY2014Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	819151	USD
CY2015Q1	us-gaap	Inventory Net InventoryNet	702921	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	537566	USD
CY2015Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	148498	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	700462	USD
CY2015Q1	us-gaap	Assets Current AssetsCurrent	14881722	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	7607006	USD
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	330308	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	245821	USD
CY2015Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	652237	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	615798	USD
CY2015Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	982545	USD
CY2014Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	861619	USD
CY2015Q1	us-gaap	Assets Assets	15864267	USD
CY2014Q4	us-gaap	Assets Assets	8468625	USD
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	475213	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	698307	USD
CY2015Q1	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	733869	USD
CY2014Q4	ctso	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	824884	USD
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	833	USD
CY2015Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	4989344	USD
CY2014Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2981418	USD
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6198426	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4505442	USD
CY2015Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	9665841	USD
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15864267	USD
CY2015Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3526	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3756	USD
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2015Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24678415	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23304640	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23304640	shares
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24678415	shares
CY2015Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	703658	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	569243	USD
CY2015Q1	us-gaap	Revenue From Grants RevenueFromGrants	18583	USD
CY2014Q1	us-gaap	Revenue From Grants RevenueFromGrants	491262	USD
CY2015Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	833	USD
CY2014Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	1667	USD
CY2015Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138180345	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	128106297	USD
CY2015Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	571880	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	227701	USD
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129111062	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-124394120	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	3963183	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8468625	USD
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	24678	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	23305	USD
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	723074	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1062172	USD
CY2015Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	304481	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	662537	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	418593	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-4716942	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-975083	USD
CY2015Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	399635	USD
CY2014Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-137089	USD
CY2015Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2007926	USD
CY2014Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-316200	USD
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2005313	USD
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	179111	USD
CY2015Q1	ctso	Stock Issued During Period Value Stock Cash Warrants Exercised StockIssuedDuringPeriodValueStockCashWarrantsExercised	593250	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-4716942	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-975083	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	951028	USD
CY2015Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4372763	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-974250	USD
CY2015Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63580	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9408584	USD
CY2015Q1	ctso	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised		USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	236774	USD
CY2015Q1	us-gaap	Professional Fees ProfessionalFees	215518	USD
CY2014Q1	us-gaap	Professional Fees ProfessionalFees	236533	USD
CY2015Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1963676	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1080522	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	3130222	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	1553829	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2711629	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1154194	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2613	USD
CY2014Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1114516	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4716942	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2089599	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24394474	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10619195	shares
CY2015Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	344179	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	833	USD
CY2015Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		USD
CY2015Q1	ctso	Stock Issued During Period Value Stock Cash Options Exercised StockIssuedDuringPeriodValueStockCashOptionsExercised	10007	USD
CY2015Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		USD
CY2014Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	90100	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21125	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	19591	USD
CY2015Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	82781	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	63580	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	57372	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-104425	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-125696	USD
CY2015Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	140711	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-99085	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-543085	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-412281	USD
CY2015Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	7134	USD
CY2015Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	339000	USD
CY2015Q2	ctso	Share Based Compensation Arrangement By Share Based Payment Award Non Vested Options Vested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonVestedOptionsVestedNumber	566000	shares
CY2015Q1	ctso	Share Based Compensation Arrangement By Sharebased Payment Award Nonvested Options Grant Date Fair Value ShareBasedCompensationArrangementBySharebasedPaymentAwardNonvestedOptionsGrantDateFairValue	1388000	USD
CY2015Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10007	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51760	USD
CY2015Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	593250	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		USD
CY2014Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-283500	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-240736	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-833	USD
CY2014Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-154995	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2408979	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-800108	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104005	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	21370	USD
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	36167	USD
CY2014Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	4541	USD
CY2015Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	1246547	USD
CY2014Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments		USD
CY2015Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2241000	USD
CY2014Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4745000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1134625	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4770911	USD
CY2015Q1	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	9408584	USD
CY2014Q1	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	9751455	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10011841	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9803215	USD
CY2015Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	345110	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	833	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6813347	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4233029	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2183030	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6416059	USD
CY2014Q1	us-gaap	Interest Paid InterestPaid		USD
CY2015Q1	ctso	Fair Value Warrant Liability Upon Issuance FairValueWarrantLiabilityUponIssuance		USD
CY2014Q1	ctso	Fair Value Warrant Liability Upon Issuance FairValueWarrantLiabilityUponIssuance	862920	USD
CY2015Q1	us-gaap	Stock Issued1 StockIssued1		USD
CY2014Q1	us-gaap	Stock Issued1 StockIssued1	7137	USD
CY2015Q1	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	903916	USD
CY2014Q1	ctso	Supplemental Noncash Transactions SupplementalNoncashTransactions	748545	USD
CY2015Q1	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid		USD
CY2014Q1	ctso	Preferred Dividends Accrued Not Yet Paid PreferredDividendsAccruedNotYetPaid	1114516	USD
CY2015Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <div class="CursorPointer"> <table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"> <tr style="vertical-align: top;"> <td style="padding: 0px; text-indent: 0px; font-family: 'times new roman'; width: 2%;"><font style="font-size: 10pt;"><b> </b></font></td> <td style="padding: 0px; text-indent: 0px; font-family: 'times new roman'; width: 2%;"><font style="font-size: 10pt;"><b>1.</b></font></td> <td style="text-align: justify; padding: 0px; text-indent: 0px; font-family: 'times new roman'; width: 96%;"><font style="font-size: 10pt;"><b>BASIS OF PRESENTATION</b></font></td> </tr> </table> </div> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company's interim financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair statement of the Company's financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim financial statements should be read in conjunction with the audited financial statements and accompanying notes for the year ended December 31, 2014 included in the Company's Annual Report on Form 10-K. The results for the three months and nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company believes that it has adequate funding for more than the next twelve months of operations, however, it may have to raise additional capital to fund its future operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">As of March 31, 2015, the Company had an accumulated deficit of $<font>129,111,062</font>, which included net losses of $<font>4,716,942</font> for the three months ended March 31, 2015 and $<font>975,083</font> for the three months ended March 31, 2014. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">The Company's losses have resulted principally from costs incurred in the research and development of the Company's polymer technology and selling, general and administrative expenses. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other selling, general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company's ability to achieve profitability will depend, among other things, on successfully completing the development of the Company's technology and commercial products, obtaining additional requisite regulatory approvals in markets not covered by the CE Mark and for potential label extensions of the Company's current CE Mark, establishing manufacturing and sales and marketing arrangements with third parties, and raising sufficient funds to finance the Company's activities. No assurance can be given that the Company's product development efforts will be successful, that the Company's current CE Mark will enable us to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of the Company's products will be manufactured at a competitive cost and will be of acceptable quality, or that the Company will be able to achieve profitability or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company's ability to continue as a going concern. These consolidated financial statements do not include any adjustments related to the outcome of this uncertainty.</font></p> </div>
CY2015Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><b>Reclassifications</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;">Certain reclassifications have been made to the March 31, 2014 financial statements in order to conform to the 2015 financial statement presentation. There was no change in the reported amount of the accumulated deficit as a result of these reclassifications.</p> </div>
CY2015Q1	us-gaap	Use Of Estimates UseOfEstimates	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities. Actual results could differ from these estimates. Significant estimates in these financials are the valuation of options granted, the valuation of preferred shares issued as stock dividends and valuation methods used to determine the fair value of the warrant liability.</p> </div>
CY2015Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"><b>Concentration of Credit Risk</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;">As of March 31, 2015, <font>three</font> distributors accounted for approximately <font>55</font>% of outstanding grant and accounts receivable. At December 31, 2014, <font>three</font> distributors accounted for approximately <font>53</font>% of outstanding grant and accounts receivable. For the three months ended March 31, 2015, approximately <font>42</font>% of revenues were from <font>three</font> distributors. No other agency, distributor, or direct customer represented more than 10% of the Company's revenue. For the three months ended March 31, 2014, approximately <font>46</font>% of revenues were from <font>two</font> U.S. government grant agencies, and no other agency, distributor, or direct customer represented more than 10% of the Company's revenue.</p> </div>
CY2015Q1	ctso	Number Of Countries In Which Product Marketed NumberOfCountriesInWhichProductMarketed	29	item
CY2014Q4	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	25	pure
CY2015Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	448509	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	12000	USD
CY2015Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1916293	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	142693	USD
CY2015Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	452949	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	326047	USD
CY2015Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	58343	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	68826	USD
CY2015Q1	us-gaap	Advertising Expense AdvertisingExpense	51000	USD
CY2014Q1	us-gaap	Advertising Expense AdvertisingExpense	116000	USD
CY2015Q1	us-gaap	Freight Costs FreightCosts	41000	USD
CY2014Q1	us-gaap	Freight Costs FreightCosts	24000	USD
CY2014Q1	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	1114516	USD
CY2015Q1	ctso	Underwriters Expenses UnderwritersExpenses	85000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	736000	shares
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	816000	shares
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	64000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	816000	shares
CY2014Q1	ctso	Fair Value Warrant Liability Upon Issuance FairValueWarrantLiabilityUponIssuance	862920	USD
CY2014Q1	us-gaap	Share Price SharePrice	6.00
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1250000	shares
CY2015Q1	us-gaap	Share Price SharePrice	8.25
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10312500	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9409000	USD
CY2015Q1	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableAggregateIntrinsicValue	18350000	USD
CY2015Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1521479	shares
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	874530	shares
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	11000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.21
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	106620	shares
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0.06
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	384326	shares
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	0.06
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	394584	shares
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.07
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2302187	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.37
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	11000	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.40
CY2015Q1	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm	P5Y6M
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	106620	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.88
CY2015Q1	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm	P9Y2M12D
CY2015Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	11396	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.18
CY2015Q1	ctso	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm	P6Y1M6D
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2015Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2195171	shares
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.39
CY2015Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
CY2015Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2015Q1	dei	Amendment Flag AmendmentFlag	false
CY2015Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q1	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
CY2015Q1	dei	Trading Symbol TradingSymbol	ctso
CY2015Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2015Q1	dei	Entity Registrant Name EntityRegistrantName	Cytosorbents Corp
CY2015Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001175151
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24764744	shares
CY2015Q1	dei	Document Type DocumentType	10-Q

Files In Submission

Name	View Source	Status
0001144204-15-028999-index-headers.html	Edgar Link	pending
0001144204-15-028999-index.html	Edgar Link	pending
0001144204-15-028999.txt	Edgar Link	pending
0001144204-15-028999-xbrl.zip	Edgar Link	pending
ctso-20150331.xml	Edgar Link	completed
ctso-20150331.xsd	Edgar Link	pending
ctso-20150331_cal.xml	Edgar Link	unprocessable
ctso-20150331_def.xml	Edgar Link	unprocessable
ctso-20150331_lab.xml	Edgar Link	unprocessable
ctso-20150331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v409247_10q.htm	Edgar Link	pending
v409247_ex31-1.htm	Edgar Link	pending
v409247_ex31-2.htm	Edgar Link	pending
v409247_ex32-1.htm	Edgar Link	pending
v409247_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTSO
Cytosorbents Corp Stock $ctso

2015 Q1 Form 10-Q Financial Statement

#000114420415028999 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO Cytosorbents Corp Stock $ctso

2015 Q1 Form 10-Q Financial Statement

#000114420415028999 Filed on May 11, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTSO
Cytosorbents Corp Stock $ctso